# EMERALD-Y90 (NCT06040099)

> A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06040099
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Hepatocellular Carcinoma (HCC)
- Interventions: Durvalumab; Bevacizumab; Transarterial Radioembolization (TARE)
- Enrollment: 58
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- YouTube: 10
- Podcasts: 5
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=emerald-y90-nct06040099

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06040099", "email": "<work email>"}; the inbox owner confirms by the emailed link.